stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) EPS (diluted)
Ionis Pharmaceuticals, Inc.'s EPS (diluted) for fiscal 2025 was −$2.38, compared with −$3.04 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$3.46. Over the past ten years it has ranged from −$3.23 (fiscal 2020) to $2.07 (fiscal 2018); the current reading is higher than 36% of that period. Ionis Pharmaceuticals, Inc. ranks 399th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$2.38 | — |
| FY2024 | −$3.04 | — |
| FY2023 | −$2.56 | — |
| FY2022 | −$1.90 | — |
| FY2021 | −$0.20 | — |
| FY2020 | −$3.23 | — |
| FY2019 | $1.90 | (8.21%) |
| FY2018 | $2.07 | — |
| FY2017 | −$0.09 | — |
| FY2016 | −$0.50 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.69 | — |
| Mar 2026 | −$0.56 | — |
| Dec 2025 | −$1.41 | — |
| Sep 2025 | −$0.80 | — |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $2.24 |
| ORKA Oruka Therapeutics, Inc. compare | −$2.12 |
| CGON CG Oncology, Inc. compare | −$2.69 |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$2.73 |
| IMVT Immunovant, Inc. compare | −$2.82 |
| AXSM Axsome Therapeutics, Inc. compare | −$3.06 |
| IONS Ionis Pharmaceuticals, Inc. | −$3.46 |
| KOD Kodiak Sciences Inc. compare | −$4.19 |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$15.22 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on IONS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement